Moody’s Analytics Tops 14 International Categories in FocusEconomics Analyst Forecast Awards
Moody’s Analytics, a global provider of financial intelligence, ranks #1 in 14 international categories in the 2020 FocusEconomics Analyst Forecast Awards. These awards include #1 Best Overall Forecaster – Hong Kong, plus the top ranking in five other forecast categories across 12 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005200/en/
#1 Best Overall Forecaster – Hong Kong
#1 Interest Rate Forecaster – Austria
#1 Interest Rate Forecaster – Italy
#1 Interest Rate Forecaster – Portugal
#1 Interest Rate Forecaster – Bahrain
#1 Inflation Forecaster – Belgium
#1 Inflation Forecaster – Malaysia
#1 Current Account Forecaster – Brazil
#1 Current Account Forecaster – Uruguay
#1 Fiscal Balance Forecaster – Croatia
#1 Fiscal Balance Forecaster – Peru
#1 GDP Forecaster – Malaysia
#1 GDP Forecaster – Slovenia
#1 GDP Forecaster – Tunisia
We also took second or third place in an additional 29 categories including:
#2 Best Overall Forecaster – Singapore
#2 GDP Forecaster – Brazil
#3 Best Overall Forecaster – Japan
“We’re pleased to earn this recognition from FocusEconomics, as it directly reflects the accuracy of our economic forecast scenarios,” said Cris deRitis, Deputy Chief Economist at Moody’s Analytics. “Our clients need trustworthy forecasts now more than ever, and can rely on ours to manage risk, implement accounting standards, and make strategic decisions with confidence.”
With the help of the Moody’s Analytics Global Macroeconomic Model, our economists generate economic forecasts for more than 100 countries interlinked by trade flows, financial markets, prices, and investments. Each month, the baseline scenario projects our view of the most likely path for the global economy, while a further 11 forecast scenarios project alternative economic paths under different assumptions.
To help users, each scenario is assigned a probability based on its relative severity. They are available for download in various file formats, through an Excel Add-In, via API programmatically, or by custom delivery. Clients can also adjust the forecast assumptions and create their own scenarios using the Moody’s Analytics Scenario Studio platform, which supports rigorous governance processes and real-time collaboration among multiple users.
To determine its annual rankings, FocusEconomics examines the accuracy of forecasts submitted to its monthly survey over a 22-month period. Their survey covers 89 countries (on six main macroeconomic indicators) as well as 22 commodities. Our results in this year’s rankings reflect the accuracy of our macroeconomic forecasts for those key indicators between January 2018 and October 2019.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn.
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,300 people worldwide and maintains a presence in 40 countries.
Moody’s Analytics Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer15.7.2020 23:30:00 EEST | Press release
LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell engaging bispecific antibodies for cancer immunotherapy, today announced the China National Medical Products Administration (NMPA) authorized the company to proceed with a Phase III trial (clinicaltrials.gov: NCT04222114) for catumaxomab in patients with peritoneal carcinomatosis, a form of advanced gastric cancer that has spread to the tissue that lines the abdominal cavity. The two-stage, multi-center, open-label, randomized, controlled registrational clinical trial will evaluate the safety and efficacy of an intraperitoneal infusion of the bi-specific antibody catumaxomab into the abdominal cavity in patients with peritoneal carcinomatosis. LintonPharm also recently received Clinical Trial Application (CTA) authorization for the same indication from the Taiwan Ministry of Health and Welfare (MOHW) and the Korea Ministry of Food and Drug Safety (MFDS). “We are excited to
Xerox Launches ConnectKey-Enabled AltaLink Digital Workplace Assistant15.7.2020 19:47:00 EEST | Press release
Xerox announced its new Xerox AltaLink® C8100 and Xerox AltaLink B8100 Series multi-function printers (MFPs), that can better support today’s flexible work environment and help companies speed their digital transformation with access to the ConnectKey® ecosystem of apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005746/en/ The tablet-like user interface allows for easy, familiar interaction or the user can choose to print from their mobile devices. (Photo: Business Wire) In addition to its printing capabilities, the AltaLink 8100 series helps speed workplace digitization with ultra-fast scanning of up to 270 images per minute and Optical Character Recognition that allows clients to extract more value from information. Combined with ConnectKey apps, including connections to the most popular cloud solutions, these printers can support a key area of focus for businesses as they shift from physical to digital enterpri
Bureau Veritas Launches a New Solution to Improve Supply Chain Resilience15.7.2020 18:45:00 EEST | Press release
Bureau Veritas , a world leader in testing, inspection and certification (TIC) services, is launching Supply-R, a solution designed to meet companies’ new challenges relating to supplier network reliability and ensuring business continuity in all circumstances. Organizations learned multiple lessons during the first half of 2020 on the resilience of global supply chains and their ability to face disruptions. There is an urgent need from many companies to reassess their supply chain risk, based on factual data from the field, to make sure that all elements are properly addressed, assessed and visible. Bruno Ferreyra, Executive Vice-President at Bureau Veritas, commented: "Economic globalization means supply chains include more suppliers and intermediaries than before, and they are scattered around the globe. This makes each step, process and stakeholder in the manufacturing chain harder to track. Our goal is to support businesses, mapping out their supply chains to give them complete co
VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors15.7.2020 18:40:00 EEST | Press release
Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors. Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The first visit of this first subject, a few days after obtaining both ANSM 1 approval and the favorable decision from the CPP 2 , marks the concrete launch of the REVERSE-IT study, the results of which are expected in mid-2022. We are right on schedule and are delighted to be able to enter the operational phase of this major study so quickly. We also welcome the enthusiasm and commitment of all the partner investigation centers." Dr Hans-Juergen WOERLE, Chief Scientific and Medical
Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients15.7.2020 18:04:00 EEST | Press release
Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group. The study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen. In critically ill COVID-19 patients, the cause of death often implicates an abnormal pulmonary immune response. This abnormal immune response is characterized by high levels of inflammatory markers, which are associated with poor clinical outcomes.1, 2 Acute respiratory distress syndrome (ARDS) and multiorgan failure are major causes of mortality in COVID-19 patients.3 High levels of pro-inflammatory cytokines and chemokines are part of a severe inflammatory response known as a “cytokine storm” which may cause multiple organ dysfunction and ARDS in criti
European Commission approves third nintedanib indication in pulmonary fibrosis115.7.2020 16:34:00 EEST | Press release
Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality simila
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom